AU2014370186A1 - Pyrazolo[1,5-a]pyridine derivatives and methods of their use - Google Patents

Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Info

Publication number
AU2014370186A1
AU2014370186A1 AU2014370186A AU2014370186A AU2014370186A1 AU 2014370186 A1 AU2014370186 A1 AU 2014370186A1 AU 2014370186 A AU2014370186 A AU 2014370186A AU 2014370186 A AU2014370186 A AU 2014370186A AU 2014370186 A1 AU2014370186 A1 AU 2014370186A1
Authority
AU
Australia
Prior art keywords
fluoro
compound
pyrazolo
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014370186A
Other languages
English (en)
Other versions
AU2014370186A2 (en
Inventor
Robert L. Hudkins
Allison L. Zulli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ignyta Inc
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of AU2014370186A1 publication Critical patent/AU2014370186A1/en
Publication of AU2014370186A2 publication Critical patent/AU2014370186A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014370186A 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use Abandoned AU2014370186A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
US61/920,819 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (2)

Publication Number Publication Date
AU2014370186A1 true AU2014370186A1 (en) 2016-07-14
AU2014370186A2 AU2014370186A2 (en) 2016-07-21

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014370186A Abandoned AU2014370186A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Country Status (22)

Country Link
US (2) US9914731B2 (https=)
EP (2) EP3309160A1 (https=)
JP (1) JP2017500362A (https=)
KR (1) KR20160110390A (https=)
CN (1) CN106029661B (https=)
AU (1) AU2014370186A1 (https=)
BR (1) BR112016015057A2 (https=)
CA (1) CA2934667A1 (https=)
CL (1) CL2016001604A1 (https=)
DK (1) DK3087070T3 (https=)
EA (2) EA201890061A3 (https=)
ES (1) ES2654931T3 (https=)
HU (1) HUE037579T2 (https=)
IL (1) IL246311A0 (https=)
MX (1) MX2016008445A (https=)
NO (1) NO3014707T3 (https=)
PH (1) PH12016501232A1 (https=)
PL (1) PL3087070T3 (https=)
PT (1) PT3087070T (https=)
SG (1) SG11201605207PA (https=)
SI (1) SI3087070T1 (https=)
WO (1) WO2015100117A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000808A2 (pt) * 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
US10703757B2 (en) 2016-12-23 2020-07-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2019101178A1 (zh) * 2017-11-24 2019-05-31 南京明德新药研发股份有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
AU2019323455B9 (en) * 2018-08-24 2024-10-24 Transthera Sciences (Nanjing), Inc. Novel quinoline derivative inhibitor
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN117720520A (zh) 2020-03-30 2024-03-19 和记黄埔医药（上海）有限公司 酰胺类化合物及其用途
US20240317692A1 (en) * 2021-07-13 2024-09-26 Nippon Soda Co., Ltd. Method for producing uracil compound
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l，2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
WO2025034912A2 (en) * 2023-08-07 2025-02-13 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
BRPI0708615A2 (pt) * 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
EP2103620A1 (en) * 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
EP3795573B1 (en) * 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
WO2012116217A1 (en) * 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2013022519A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
EP2780338B1 (en) * 2011-11-14 2016-11-09 Ignyta, Inc. Uracil derivatives as axl and c-met kinase inhibitors
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
HUE037579T2 (hu) 2018-09-28
EA201691164A1 (ru) 2016-12-30
PL3087070T3 (pl) 2018-03-30
KR20160110390A (ko) 2016-09-21
DK3087070T3 (en) 2017-12-04
JP2017500362A (ja) 2017-01-05
SG11201605207PA (en) 2016-07-28
CN106029661B (zh) 2017-11-03
BR112016015057A2 (pt) 2017-08-08
US20180148447A1 (en) 2018-05-31
SI3087070T1 (en) 2018-01-31
EA201890061A2 (ru) 2018-05-31
US9914731B2 (en) 2018-03-13
EA201890061A3 (ru) 2018-09-28
CA2934667A1 (en) 2015-07-02
ES2654931T3 (es) 2018-02-15
MX2016008445A (es) 2016-10-28
AU2014370186A2 (en) 2016-07-21
PH12016501232A1 (en) 2016-08-15
EP3309160A1 (en) 2018-04-18
US20160318929A1 (en) 2016-11-03
NO3014707T3 (https=) 2018-01-06
WO2015100117A1 (en) 2015-07-02
CN106029661A (zh) 2016-10-12
EP3087070B1 (en) 2017-11-08
PT3087070T (pt) 2018-01-30
EA029757B1 (ru) 2018-05-31
IL246311A0 (en) 2016-08-02
CL2016001604A1 (es) 2017-05-26
EP3087070A1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
EP3087070B1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
KR101467593B1 (ko) Ｆｇｆｒ 억제제로서의 아실아미노피라졸
US10112954B2 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
CN110551105B (zh) 用作axl抑制剂的取代三唑
AU2008225766B2 (en) Organic compounds and their uses
ES2297498T3 (es) Composiciones utiles como inhibidores de proteina quinasas.
KR102038462B1 (ko) Pi3k의 활성 또는 기능의 억제제의 용도
US20080113967A1 (en) Enzyme modulators and treatments
MX2014008647A (es) Compuesto de pirazin-carboxamida.
CN107635986A (zh) 取代的喹喔啉衍生物
JP2009541268A (ja) Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
WO2012008563A1 (ja) 含窒素芳香族複素環誘導体
TW200914023A (en) Compounds and compositions as kinase inhibitors
NZ584573A (en) Heterocyclic compound and pharmaceutical composition thereof
KR20140120371A (ko) Ｔｂｋ1 및 ｉｋｋ 저해제로서의 푸로 [3, 2 - ｂ] - 및 티에노 [3, 2 - ｂ] 피리딘 유도체
WO2012044090A2 (ko) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
US20250179013A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
WO2013100672A1 (ko) 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체
CA2607874A1 (en) Quinoline derivatives as neurokinin receptor antagonists
JP2024528729A (ja) Ｓｒｐｋインヒビター
CN120398829A (zh) 2-胺基取代氮杂芳环类化合物及其药物组合物和应用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 JUN 2016

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted